New pill could delay kidney failure in thousands
NCT ID NCT07419828
First seen Mar 06, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tests an experimental drug called HRS-1780 in about 2,000 adults with chronic kidney disease. The goal is to see if adding HRS-1780 to standard care can slow the loss of kidney function better than a placebo. Participants take the drug or placebo for 32 months while doctors monitor kidney health through blood and urine tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
RECRUITINGNanjing, Jiangsu, 210002, China
Contact
Conditions
Explore the condition pages connected to this study.